A Case of Retinal Tear Associated with Use of Sorafenib

Authors :: Kelly M. Gaertner
Stephen H. Caldwell
Osama E. Rahma
Source :: Frontiers in Oncology, Frontiers in Oncology, Vol 4 (2014)
Publication Year :: 2014
Publisher :: Frontiers Media S.A., 2014.
Abstract: Inhibition of angiogenesis is a target in the treatment of a variety of malignancies. Sorafenib is an oral inhibitor of multiple tyrosine kinases involved in tumor angiogenesis. A related case of ophthalmologic toxicity has been reported with another vascular endothelial growth factor receptor inhibitor, sunitinib. We report the first case of retinal tear possibly associated with sorafenib.

Tools